Haotian Lin, MD, PhD
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China
Dr. Haotian Lin is currently the Vice President, the Director of Artificial Intelligence and Big Data Department of Zhongshan Ophthalmic Center of Sun Yat-Sen University,the Primary Investigator, the PhD tutor and the professor of Center for Precision Medicine of Sun Yat-Sen University. He is the Chief Scientist of National Key R&D Program of China, working on the transformation and application of medical big data in medical artificial intelligence. He serves as the deputy chairman of Intelligent Medical Special Committee of Chinese Association for Artificial Intelligence. He is a member of All-China Youth Federation, a youth member of ophthalmic division of Chinese Medical Association, the vice chairman and the secretary of Guangdong Association of Young scientists. He is expert in phacoemulsification and intraocular lens (IOL) implantation, particularly in the prevention and treatment for congenital cataract. He has constructed the rare disease database of ophthalmology (Science 2015), created the world’s first intelligent cloud platform for cataract diagnosis and treatment (Nat. Biomed. Eng. 2017, cover paper). He also designed the visual evaluation system for infants via deep learning(Nat. Biomed. Eng. 2019, cover paper), and the intelligent myopia prediction system for adolescents (PLoS Medicine 2018). He established the world’s first ophthalmic artificial intelligence robot clinic, the one and only selected Chinese project, which was ranked as “11 milestones in the global medical artificial intelligence field” by IEEE Spectrum (“AI vs. Doctors”). He launched the world’s first artificial intelligence multicenter clinical controlled trial research (Eclinicalmedicine 2019, cover paper), which reported as the “Key Advances” of Ministry of Science and Technology of China. He developed a number of medical equipment and software successfully applied to clinic. He has edited 2 books as the editor-in-chief, co-written 6 monographs and published more than 100 SCI papers as the first or the corresponding author, including Nature, Science, Lancet, BMJ, Nature Biomedical Engineering, PLoS Med, EClinicalMedicine, etc. He owned more than 10 patents from China and the US with exceeding additional 20 patents filed.
|
